Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 15/20 | 0.73 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.59 |
| ▸ | KIT | P10721 | 1/20 | 0.59 |
| ▸ | PANK3 | Q9H999 | 5/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13751779 | 1.00 | FLT3 (0.73) | FLT3PDGFRBKITPANK3 | |
| SCHEMBL14596996 | 0.91 | FLT3 (0.61) | FLT3PDGFRBKITPANK3 | |
| SCHEMBL3882199 | 0.91 | FLT3 (0.61) | FLT3PDGFRBKITPANK3 | |
| SCHEMBL13956287 | 0.91 | FLT3 (0.61) | FLT3PDGFRBKITPANK3 | |
| SCHEMBL4963769 | 0.85 | FLT3 (0.63) | FLT3PDGFRBKIT | |
| SCHEMBL4963757 | 0.85 | FLT3 (0.63) | FLT3PDGFRBKIT | |
| SCHEMBL27734123 | 0.84 | FLT3 (1.00) | FLT3PDGFRBKIT | |
| SCHEMBL13955962 | 0.84 | FLT3 (1.00) | FLT3PDGFRBKIT | |
| SCHEMBL3888711 | 0.80 | FLT3 (0.67) | FLT3PDGFRBKIT | |
| SCHEMBL3888708 | 0.80 | FLT3 (0.67) | FLT3PDGFRBKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1898917-B1 | AMINOPYRIMIDINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-01-14 | — | — | EP | disclosed |
| EP-1898917-A1 | AMINOPYRIMIDINES AS KINASE MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2008-03-19 | — | — | EP | disclosed |
| US-20070021435-A1 | AMINOPYRIMIDINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-25 | — | — | US | disclosed |
| WO-2006135719-A1 | AMINOPYRIMIDINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
| US-20060281755-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS | BAUMANN CHRISTIAN A | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021435-A1 | AMINOPYRIMIDINES AS KINASE MODULATORS | FLT3, KIT, TK1 | FLT3 1/4885PDGFRB 22/4885KIT 2/4885 |
| US-20060281755-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS | FLT3, CSF3R, CSF1R | FLT3 1/4885PDGFRB 70/4885KIT 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.